13.06.2015 Views

Winter News 2013 - Beating Bowel Cancer

Winter News 2013 - Beating Bowel Cancer

Winter News 2013 - Beating Bowel Cancer

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Care and support<br />

Patient Services<br />

National Colorectal <strong>Cancer</strong> Nurses<br />

Network Conference<br />

In October we were delighted to<br />

organise the National Colorectal<br />

<strong>Cancer</strong> Nurses Network’s annual<br />

conference in London, which was attended by 70<br />

colorectal and stoma nurses.<br />

The delegates were given presentations on a wide<br />

variety of subjects ranging from the <strong>Cancer</strong> Drugs<br />

Fund to bowel management after rectal cancer to selfmanagement<br />

pathways. To wind up a very successful<br />

day of learning and networking, one of our <strong>Bowel</strong><br />

<strong>Cancer</strong> Voices, Hazel Elkamouri, gave a patient<br />

perspective on the challenges of coping with advanced<br />

bowel cancer.<br />

What the nurses valued most from the day was the<br />

opportunity to network with other colleagues and share<br />

experiences.<br />

New Chemotherapy Drugs<br />

There are two new drugs<br />

in the pipeline to treat<br />

advanced bowel cancer;<br />

both have been licenced<br />

by the US Food & Drug<br />

Administration, and await<br />

approval here in the UK.<br />

Zaltrap (aflibercept) is<br />

a targeted therapy which<br />

aims to block the growth<br />

of blood vessels to<br />

tumours (angiogenesis).<br />

In a large study of patients<br />

with previously treated<br />

advanced bowel cancer,<br />

aflibercept in combination<br />

with chemotherapy<br />

(FOLFIRI) was shown<br />

to help some patients<br />

to live longer.<br />

Stivarga (regorafenib)<br />

is an oral medicine which<br />

targets key proteins that<br />

are essential for the<br />

survival of the cancer cell.<br />

By specifically targeting<br />

these proteins, regorafenib<br />

may stop cancer growth or<br />

reduce the growth of the<br />

tumour.<br />

There are clinical trials<br />

available for both of these<br />

drugs – contact us if you<br />

would like further details.<br />

New Member<br />

of our Medical<br />

Advisory Board<br />

We are delighted to<br />

welcome to our<br />

Medical Advisory Board<br />

Mr Hassan Z Malik, a<br />

consultant hepatobiliary<br />

surgeon and clinical lead<br />

for liver surgery at<br />

University Hospital<br />

Aintree. Appointed to<br />

the hospital in 2007, he<br />

has introduced complex<br />

liver surgical techniques<br />

within the unit and his<br />

areas of clinical interest<br />

include the management<br />

of colorectal liver<br />

metastases.<br />

Mr Hassan Z Malik<br />

Consultant hepatobiliary<br />

surgeon and clinical lead for<br />

liver surgery at University<br />

Hospital Aintree.<br />

www.beatingbowelcancer.org 9

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!